Drugs / trimethoprim/sulfamethoxazole
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03014687 | Jul 2017 → Jan 2019 overdue | pituitary gland adenoma | St. Joseph's Hospital and Medical Center, Phoenix | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | trimethoprim/sulfamethoxazole | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03014687 ↗ |
| Route | Oral | “Oral antibiotics (cefdinir [Omnicef®] 300 mg PO BID or trimethoprim/sulfamethoxazole [Bactrim DS™] PO BID for cephalosporin intolerant patients) for 7 days.” NCT03014687 ↗ |